2007
News
September 6, 2007: Allan B. Haberman, Ph.D.,
was quoted in two articles on the metabolic disease drugs lorcaserin (Arena Pharmaceuticals)
and exenatide (Amylin/Lilly's Byetta) on the Pharmawire news service. The articles
were published on September 4 and September 6, respectively.
Pharmawire
is an online subscription-based news service that focuses on news and data on
the global pharmaceutical market. It is owned by the Financial Times Group, the
publisher of the Financial Times.
April 27,
2007: Cambridge Healthtech Institute (CHI) announced the publication of a
new book-length report, Diabetes and Its Complications: Strategies to Advance
Therapy and Optimize R&D, by Allan B. Haberman, Ph.D.
This new Insight Pharma Report (formerly Advances Reports), provides a strategic
perspective on the field of drugs for diabetes and its complications, with an
emphasis on novel and emerging drugs and therapeutic strategies.
The
report will be of special interest to you if you are involved in the research,
development, licensing, or portfolio management of current and potential diabetes
therapies. It will also be of interest to you if you work in other metabolic disease
areas (e.g., obesity and cardiovascular disease), or if you are interested in
assessing new opportunities in metabolic diseases for your company.
For
more information on the report, or to order it, see the CHI
Insight Pharma Reports website.
March 7, 2007:
Allan B. Haberman, Ph.D. was quoted in an article entitled "FDA and Acomplia:
Stuck on Each Other?" by Beth Herskovits, in the March 7 issue of Pharmaceutical
Executive's weekly newsletter PharmExec Direct. The article was about
antiobesity drugs, with the focus on Sanofi-Aventis' Acomplia (rimonabant).
The
article is available at http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=409028
